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ABSTRACT
Introduction: Cardiovascular disorders are one of the leading causes of mortality and morbidity 
worldwide. Recent advances showed a promising role of proprotein convertase subtilisin/kexin type 9 
(PCSK9) as a critical player in regulating plasma LDL levels and lipid metabolism.
Areas covered: This review addresses the molecular functions of PCSK9 with a vision on the clinical 
progress of utilizing monoclonal antibodies and other biological approaches to block PCSK9 activity. 
The successful clinical trials with monoclonal antibodies are reviewed. Recent advances in (pre)clinical 
trials of other biological approaches, such as small interfering RNAs, are also discussed.
Expert opinion: Discovery of PCSK9 and clinical use of its inhibitors to manage lipid metabolism is a 
step forward in hypolipidaemic therapy. A better understanding of the molecular activity of PCSK9 can 
help to identify new approaches in the inhibition of PCSK9 expression/activity. Whether if PCSK9 plays a 
role in other cardiometabolic conditions may provide grounds for further development of therapies.
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1. Introduction
PCSK9 is a protein from the family of secretory proteases 
responsible for the proteolytic activation of protein precursors 
[1]. PCSK9 is mainly produced within the hepatocyte; however, 
other cell types can produce and secrete the protein, whether 
this extrahepatic production has a systemic role remains to be 
addressed [2]. The PCSK9 protein consists of 692-aminoacids, 
including a signal peptide, a pro-domain, a subtilisin-like cat-
alytic domain and a variable C-terminal domain. Two forms of 
PCSK9 are found in plasma, a 63 kDa and 55 kDa protein [3]. 
The mature protein of 63 kDa is produced in the endoplasmic 
reticulum (ER) as a result of the removal of pro-PCSK9’s signal 
peptide followed by autocatalytic cleavage of the pro-domain, 
which in turn can associate to the catalytic domain inhibiting 
PCSK9 activity [4]. The 52–55 kDa truncated type is generated 
mainly by furin cleavage after release; these lower molecular 
weight forms appear to have lower affinity to the LDLR [3], but 
still, the possible physiological function of this form of PCSK9 
is not clear [5]. Near to half of the circulating PCSK9 appears to 
be the truncated form [6], while the total protein level in 
plasma may widely vary in the population over a 100-fold 
range (33–2988 ng/mL), with a median value of 487 ng/mL 
[7]. This wide range is, in part, explained by gender [7], fasting 
state [8], time of the day [8], lifestyle [9], diet [10] and disease 
conditions [7]; of note, PCSK9 is also responding as an acute 
phase reacting protein [11].
Due to PCSK9 activity in the metabolism of low-density 
lipoprotein (LDL), it has become a target for treatment of 
hypercholesterolemia [12]. This function has first emerged 
by identifying an autosomal dominant familial hypercholes-
terolemia (FH) result of the Gain-of-function (GOF) muta-
tions in the PCSK9 gene [13]. Further evidence confirmed 
this observation by the identification of Loss-of-function 
(LOF) mutations in the PCSK9 gene, which correlates with 
a phenotype characterized by low LDL plasma levels and 
decreased cardiovascular risk [14]. The efficiency of PCSK9 
to orchestrate the LDL levels in blood relates to its associa-
tion with the turnover of the LDL receptor (LDLR) since the 
cellular uptake of LDL is mainly receptor-dependent [15]. 
When PCSK9 binds to the epidermal growth factor-like 
repeat domain of the LDLR, the LDL-LDLR complex cannot 
unfold in the endosomes and undergoes lysosomal degra-
dation [16]. The reduction of the surface LDLR results in 
increased plasma LDL levels while lowering plasma levels 
of PCSK9 results in an increased presence at the surface of 
the cells of the LDL receptor and as a consequence in the 
reduction of circulating LDL particles [17,18].
Currently, monoclonal antibodies (mAbs) is the only clini-
cally available pharmacological approach targeting PCSK9 to 
treat hypercholesterolemia [19]. Several other therapeutic 
approaches have been proposed for suppressing or inhibiting 
PCSK9 (Figure 1), including gene silencing agents such as 
siRNA [20] or antisense oligonucleotides [21], small peptides 
or adnectins [22], and small molecules [23]. A PCSK9 vaccine is 
also under evaluation [24]. This review covers the state of the 
art regarding the action of PCSK9 on lipoprotein metabolism 
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and the potential of new biological approaches to lower 
PCSK9 and to reduce LDL cholesterol.
2. PCSK9 and LDL metabolism
The clearance of LDL from plasma mainly occurs in hepatocytes 
throughout the LDLR mediated endocytosis [29]. PCSK9 has a 
direct effect on LDLR; but it can target other receptors as well; 
for instance, human embryonic kidney cells (HEK293) incubated 
with conditioned media containing recombinant PCSK9 showed 
decreased levels of receptors belonging to the LDLR family that 
modulate the clearance of TG-rich lipoproteins (VLDL and 
apolipoproteinE2 (ApoE) receptors), probably due to mechan-
isms involved in the lysosomal degradation pathway [30]. A link 
has also been reported between PCSK9 and apoB-100 secretion 
from the liver of FH patients carrying the GOF S127R mutation 
in PCSK9, which seems to increase the level of ApoB-100, lead-
ing to increase in VLDL, remnants and LDL plasma levels [31]. 
This effect on ApoB secretion could be a result of PCSK9- 
mediated degradation of LDLR and the consequently reduced 
LDL clearance rate, but it is also possible that PCSK9 may affect 
ApoB by binding to its N-terminal domain preventing ApoB 
autophagy [32]. The autophagosome/lysosome pathway is an 
LDLR-independent mechanism proposed for the intracellular 
degradation of ApoB, since the interaction with PCSK9 could 
shunt ApoB from degradation in autophagosome, destinating it 
for assembly of VLDL in hepatocytes [32]. In vitro studies 
showed that ApoB secretion is also stimulated in human enter-
ocytes (CaCo-2 cells) throughout LDLR dependent and indepen-
dent mechanisms, involving both transcriptional and post- 
transcriptional effects on ApoB production, stability and degra-
dation [33].
This evidence suggests that PCSK9 plays a central role in 
modulating plasma lipoprotein profile, particularly LDL, but 
other lipoproteins could be affected as well.
Article highlights
● PCSK9 is a small protein produced mainly by hepatocytes, which has 
a crucial role in modulating the clearance of LDL from plasma.
● The LDL receptors (LDLR) that have PCSK9 bound will be degraded in 
lysosomes, and this reduction of LDLR increases the levels of LDL in 
plasma.
● Blocking PCSK9 either in function (with monoclonal antibodies) or at 
its expression level (with small RNAs or other biological agents) can 
significantly reduce the plasmatic LDL-C levels and, therefore, cardi-
ovascular risks.
● The translation from bench to clinical usage of monoclonal antibo-
dies to block PCSK9 is one of the fastest in the history of drug 
development, due to its efficient and specific function on LDLR 
turnover.
This box summarizes key points contained in the article.
Figure 1. Different biological strategies to target PCSK9. To reduce the plasmatic LDL-C level, we can suppress the PCSK9 function (A). As the current approach in 
the clinics, the binding of mAbs to free PCSK9 in plasma prevents the binding to the LDLR, increasing its expression. The anti-PCSK0 MAbs bind to the catalytic 
domain of PCSK9 by neutralizing PCSK9 blocking the extracellular interaction with the EFG-A domain of LDLR [25]. Other approaches in this category are; (1) Annexin 
-A2 is an extracellular endogenous antagonist that specifically binds to the C-terminal domain of the PCSK9 at the cell surface, inhibiting the PCSK9-mediated 
degradation of LDRL. Adenoviral overexpression of AnxA2 in the liver results in an increase of LDLR expression [26]; (2) DS-9001a is a small biologic molecule, 
composed of an albumin-binding domain fused with an artificial lipocalin mutein enabling high specific recognition of the target protein. DS-9001a inhibits the 
binding of the PCSK9 to LDLR, preventing LDLR degradation [27]; (3) Adnectin, BMS-962,476 is a PCSK9-targeting polypeptide conjugated with polyethylene glycol 
which enhances its pharmacokinetic profile, binding to human PCSK9 with subnanomolar affinity. Adnectin hinders the interaction between the EGF-A domain of 
LDLR and extracellular PCSK9, thus preventing the PCSK9- induced degradation of LDLR [28]. Instead of biologically blocking the PCSK9 function, we can block its 
production at the transcript level (B). To reach this aim, there has been in clinical trial different approaches; (1) Inclisiran is a fully chemically modified and liver- 
specific siRNA directed against PCSK9. Inclisiran is composed of one 2′-deoxy, eleven 2′-fluoro-, and thirty-two 2′-O- methyl-modified nucleotides, and a triantennary 
N-acetylgalactosamine (GalNAc) that is conjugated to the 3′-end of the passenger strand. The asialoglycoprotein receptor recognizes the GALNAc inhibiting the 
uptake of Inclisiran, resulting in the reduction of PCSK9 mRNA by 70% [113]; (2) Antisense Oligonucleotides (ASOs) inhibit the PCSK9 mRNA protein synthesis 
decreasing intra and extracellular protein levels. SPC5001, the clinical grade product of this approach, is 14 base oligonucleotide relying on locked nucleic acid 
technology with higher binding and specificity for PCSK9 mRNA [12]; (3) it has been proposed to block the PCSK9 expression by targeting the ribosomal complex 
using biologically active small molecules, in this way PF-06446846 (PF846) a small active molecule has been developed that directly inhibits the translation of PCSK9 
by stalling the 80S ribosome in codon 34. The activity depends on the sequence of the nascent chain within the ribosome exit tunnel [14].
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3. PCSK9 gene regulation
The interaction of PCSK9 and LDL metabolism (Figure 2) is 
reciprocal; for instance, cholesterol deficiency or inhibition of 
intracellular cholesterol biosynthesis (as it happens with sta-
tins) upregulates PCSK9 throughout the recruitment of sterol- 
regulatory element-binding protein 1 (SREBP1) and SREBP2 
that bind to the sterol-regulatory element (SRE) in the prox-
imal promoter region of the gene [34]. Dietary Saturated Fatty 
acids (SFAs) upregulate SREBP2 that increases PCSK9 expres-
sion, while long-chain polyunsaturated fatty acids (n-3 PUFA) 
down-regulate SREBP2 probably due to modulating the phos-
phorylation of the mitogen-activated protein kinases (MAPKs) 
[10]. The administration of n-6 PUFA has been reported to 
reduce PCSK9 expression, by reducing inflammatory 
responses, via reduction of the expression of the tumor necro-
sis factor receptor 2 (TNF-R2) and interleukin-1 (IL-1) which 
upregulate SREBP2 [35]. The same effect has been reported for 
monounsaturated fatty acids (MUFAs) that can have anti- 
inflammatory effects [36]. Fasting state also decreases PCSK9 
and cholesterol biosynthesis, probably by downregulating 
SREBP2 [8]. Additionally, PUFAs can activate the peroxisome 
proliferator-activated receptors α (PPARα), leading to suppres-
sion of PCSK9 promoter’s activity and SREBP1c expression [37]. 
Following this, the activation of the Janus kinase/signal trans-
ducer and activator of transcription (JAK/STAT) pathway sup-
presses PCSK9 expression [38] while its inhibitor, the 
suppressor of cytokine-signaling-3 (SOC3), stimulates PCSK9 
expression throughout the activation of SREBP1 [39], thus 
reinforcing the link between PCSK9 and inflammation. 
Glucagon reduces hepatic PCSK9 and SREBP2 expression 
[40]. This observation suggests that other regulatory elements 
additional to SRE may be present in the PCSK9 gene promoter. 
In this way, hepatic nuclear transcription factor protein α 
(HNFα) has been found as another factor promoting PCSK9 
transcription by binding to an HNF binding motif, located 28 
base pairs upstream of the SRE site [41]. Insulin inhibits the 
HNF-induced PCSK9’s transcription by FoxO3 recruitment of 
sirtuin 6 -a protein deacetylase- in a region wholly embedded 
in the HNF1A binding site [42]. Insulin represses hepatic PCSK9 
expression mediated by HNF4α and HNF1 also in a protein 
kinase C-dependent manner [43]. The histone nuclear factor P 
(HNFP) region cooperates as well in PCSK9 transcriptional 
regulation [44]. Here, a complex composed of HINFP and its 
cofactor nuclear protein of the ataxia telangiectasia mutated 
locus (NPAT) recruits the histone acetyltransferase (HAT) cofac-
tor transformation/transactivation domain-associated protein 
(TRRAP), that facilitate the histone 4 (H4) acetylation in the 
PCSK9 promoter [45]. Current evidence indicates that the SRE 
motif in the promotor principally regulates PCSK9 expression; 
however, there are other elements on its adjacent upstream 
region that cooperate in the regulation. It is also clear that 
PCSK9 expression does not only depend on lipid metabolism 
but also factors related to glycemia and inflammation; PCSK9 
potential role in these areas is worth investigating.
4. PCSK9 translation and secretion
PCSK9, like other zymogens, passes the ER and the Golgi 
apparatus to become a mature functional protein [47]. The 
LDLR undergoes the same path and co-exists with PCSK9 in 
this secretory pathway without being affected; GRP94 is the 
ER-resident chaperon protein that prevents early binding of 
Figure 2. PCSK9 turnover in circulation and its metabolic function. Hepatocyte: LDLR activity in the absence of PCSK9 (black arrow): LDLR binds LDL and the 
complex is internalized by endocytosis. ARH is an adaptor protein that participates in the internalization of the LDL-LDLR complex. After this step, LDL is degraded 
into lysosomes while LDLR is recycled to the membrane; LDLR activity in the presence of PCSK9 (orange arrow): on the cell surface, PCSK9 binds to LDLR. The 
complex is internalized and degraded into lysosomes, preventing LDLR recycling to the membrane. HMSCs, ECs and macrophages produce PCSK9, although most of 
the protein comes from hepatocytes. Apart from hepatic effects, PCSK9 has other pleiotropic effects (dotted arrow) on the cells of the plaque. If internalized by 
macrophages, it could prevent the foam cell formation, acting on the clearance of the LDLR. PCSK9 can also modulate the recruitment of monocyte in the 
atherosclerotic plaque. It is also able to induce the expression of the OxLDLr on ECs and HSMCs surface. In HSMCs, PCSK9 has been shown to downregulate the 
expression of receptors such as LRP-1, CD36, and LDLR. 3D structural demonstration of EGF-A domain of LDLR is adopted from [46].
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the LDLR to PCSK9 [48]. Following synthesis in the ER, PCSK9 is 
transported to the Golgi apparatus into vesicles coated with 
the coat protein complex II (COPII), where the assembly relies 
on specific signals within cargo molecules, mediated by the 
SEC24 subunit of the COPII complex [49]. In mice, homozygous 
SEC24A deletion results in a phenotype characterized by upre-
gulation of the LDLR and significantly lower LDL-C levels, a 
consequence of PCSK9 dependence on SEC24A to transit from 
the ER [50], thus suggesting SEC24A as a possible biological 
target to reduce LDL. Gustafsen et al. reported a potential 
effect of Sortilin, a protein encoded by the hypercholesterole-
mia-risk gene SORT1 in modulating PCSK9 secretion, as the 
two proteins colocalize in the trans-Golgi network [51]. Further 
research is warranted to elucidate the interaction of PCSK9 
with Sortilin (Figure 2).
Annexin A2 (AnxA2) has been identified as an endogenous 
extrahepatic inhibitor of PCSK9. Extracellular AnxA2 is a mem-
brane-associated receptor for several proteins that hampers 
PCSK9 binding to the LDLR interacting with its C-terminal Cys- 
His-rich domain (CHRD), probably through the induction of 
allosteric structural changes [52]. It is highly abundant at the 
surface of endothelial cells, fibroblasts and COS-7 cells, thus 
explaining in the inability of high concentrations of injected 
PCSK9 to promote LDLR degradation in these cells [52]. 
Altogether these findings show the potential for alternative 
targets to modulate PCSK9 levels.
5. Monoclonal antibodies for cholesterol-lowering
The discovery of the PCSK9 function in lipid metabolism has 
triggered the development of pharmacological strategies to 
decrease PCSK9 levels by targeting either protein synthesis or 
its interaction with the LDLR. Treatment with mAbs is currently 
one of the best clinical strategies to deal with severe hyperch-
olesterolemia [53]. The use of mAbs for blocking PCSK9 has 
been one of the fastest translations to the clinic in the history 
of drug development (Figure 3). From the development of the 
first successful clinical-grade monoclonal antibodies, it took 
only a few years for the FDA and EMA approval for therapy 
[54]. Alirocumab and evolocumab are two fully human mono-
clonal antibodies currently approved for therapy. Antibody- 
based therapy has advantages over traditional therapies in 
terms of specificity, potency and posology. mAbs do not 
interact with cytochromes or other proteins, leading to a 
reduced risk of drug-drug interactions [19].
Alirocumab is a monomeric immunoglobulin G1 (IgG1) iso-
type; it is composed of two human heavy chains, two kappa 
light chains and a single glycosylation site. At low concentra-
tions, its elimination predominately occurs through saturable 
binding to PCSK9, while at higher concentrations it depends 
on a non-saturable proteolytic pathway; resulting in a median 
half-life at steady state of 17 to 20 days in monotherapy if 
administered once every two weeks (75 or 150 mg) [59].
Evolocumab is a dimeric immunoglobulin G2 (IgG2) isotype 
[60] composed of two lambda light chains and two heavy 
chains with glycosylated sites [61]. The recommended therapy 
regime for evolocumab is 140 mg every two weeks or 420 mg 
monthly administration [62]. It has two elimination phases, 
while it has an estimated half-life is 11–17 days [60]. A negli-
gible amount of anti-drug antibodies has been reported for 
evolocumab treated patients [63].
5.1. Clinical trials
After different preclinical and Phase I trials, Phase II clinical 
trials ended in 2012 and confirmed the encouraging results of 
the previous phases. Both alirocumab and evolocumab were 
shown to reduce LDL-C plasma levels alone successfully or in 
combination with different doses of statins and/or Ezetimibe 
(Table 1).
The OSLER 1 and 2 trials with an open-label randomized 
controlled approach examined evolocumab [70]. They 
included patients with other cardiovascular risk factors show-
ing a reduction in LDL-C levels of about 61% (Table 2). A 
similar investigation was conducted for alirocumab on the 
ODYSSEY LONG TERM study, with comparable results [71]. 
However, the first randomized controlled cardiovascular out-
come trial for evolocumab was FOURIER [72]. The 27,564 
Figure 3. Time-line of PCSK9: from discovery to therapy. [55; 13; 56; 14; 57]; [A = Sanofi report]; [58].
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patients with established atherosclerotic cardiovascular dis-
ease on statin therapy were randomized to either evolocu-
mab or placebo and monitored for the rate of major 
cardiovascular events. At 48 weeks, patients on evolocumab 
showed a 59% reduction in LDL-C as compared with those on 
statin therapy; after 26 months, evolocumab was associated 
with a 1.5% absolute risk reduction in the primary outcome. 
These effects were consistent regardless of baseline choles-
terol levels or statin dose. The subsequent analysis assessed 
the efficacy and safety of evolocumab according to the 
degree of LDL-C reduction at one month [73]. Further sub- 
analysis studies confirmed benefit from evolocumab treat-
ment also in patients with myocardial infarction (MI) [74] 
and peripheral arterial disease (PAD) [75]. Then, The 
ODYSSEY OUTCOMES trial enrolled 18,924 subjects within 1– 
12 months after acute coronary syndrome (ACS) after a run-in 
phase of 2–16 weeks on high-intensity statin therapy. 
Individuals with LDL-C ≥ 70 mg/dL were randomized to alir-
ocumab or placebo. Alirocumab injection reduced LDL-C by 
54.7%, thus reducing up to 15% cardiovascular risk if com-
pared with the placebo group [76]. SPIRE1 and 2 clinical trials 
(funded by Pfizer) have set to evaluate a humanized mono-
clonal antibody anti PCSK9, bococizumab, on patients at high 
cardiovascular risk. The trials have been stopped early due to 
development of anti-drug antibodies nevertheless the LDL-C 
reduction levels correlated well with the reduction of CVD risk 
on the patients with high CVD risk and high LDL-C values [77].
This data showed mAbs as monotherapy alone or in asso-
ciation with statins could lead to an up to 65% reduction in 
LDL-C plasma levels, thus reducing cardiovascular risk. The 
absolute reduction of cardiovascular risk, however, directly 
relates to the absolute reduction (not %) of LDL-C in plasma 
[17]. Therefore, in the ODYSSEY OUTCOMES trial, patients 
treated with alirocumab for a median of 33 months showed 
1.1 mmol/L reduction in LDL-C level that it can be considered 
up to 22% reduction in risk for cardiovascular events [83]. 
Moreover, a 25% lipoprotein little (a) (Lp(a)) reduction has 
been observed in alirocumab and evolocumab treated 
patients at long term follow up [84]; probably due to the 
similarities between LDL and Lp(a), it can be catabolized 
using LDLR-mediated pathway, this possibility, however, 
remains to be addressed. Further follow-up is essential to 
clarify mAbs’ long-term safety and efficacy.
5.2. Adverse events
The potential adverse effects of achieving long-term defi-
cient LDL-C levels in subjects on PCSK9 inhibitors (PCSK9i) 
have been evaluated. Bococizumab injections (at a substan-
tial part of patients who received the mAbs) induced a high 
level of anti-drug antibodies (ADAs) titer that lead to sig-
nificant suppression of PCSK9 inhibition [85]. As well, 
around 5% of patients who received alirocumab developed 
anti-drug antibodies -a percentage that was furthermore 
reduced to 1.3%-, but without alteration in the LDL-C reduc-
tion rate [86]. According to the OSLER-1 long term trial, 
transient ADAs rarely occurred in patients taking evolocu-
mab, and none was detected after the first-year treatment 
[63]. There were not significant neurocognitive disorders 
caused by evolocumab (EBBINGHAUS [70], REGARDS [87]), 
Table 1. Phase II clinical trials with alirocumab or evolocumab. Summary of experimental designs and their endpoint in the reduction of LDL-C plasma levels, the 
presence or absence of different adjunctive ad-hoc lipid-lowering therapies. The total recruited individuals in all of the trials were 1701.
mAb – Study Name Patients enrolled Treatment LDL reduction (%) Ref.
Evolocumab – 
LAPLACE-TIMI57
- Hypercholesterolemic (LDL-C ≥ 85 mg/dL) - Tacking Statins Evolocumab Every 2 weeks-12 weeks 70– 
105-140 mg
from 41 ± 8 to 
61 ± 1
[64]
Evolocumab Every 4 weeks −12 weeks 
280–350-420 mg
from 41 ± 8 to 
50 ± 3
Alirocumab - Hypercholesterolemic (LDL-C ≥ 100 mg/dL) 
- Taking Atorvastatin
Alirocumab Every 2 weeks-12 weeks 
50 mg 100 mg 150 mg
40 
64 
72
[65]
Alirocumab Every 4 weeks-12 weeks 
200 mg 300 mg 12 weeks
43 
48
Evolocumab – 
RUTHERFORD
- Heterozygous autosomal dominant hypercholesterolemia (LDL- 
C ≥ 100 mg/dL)  
- Taking statins ± ezetimibe
Evolocumab Every 4 weeks-12 weeks 
350 mg 420 mg
43 ± 3 
55 ± 3
[66]
Alirocumab - Heterozygous autosomal dominant hypercholesterolemia 
(LDL-C ≥ 100 mg/dL) 
- Tacking Statins ± Ezetimibe
Alirocumab Every 2 weeks-12 weeks 
150 mg
67.9 ± 4.85 [67]
Alirocumab Every 4 weeks-12 weeks 
150 mg 200 mg 300 mg
28.9 ± 5.08 
31.54 ± 4.91 
42.53 ± 5.09
Evolocumab – 
MENDEL
- Hypercholesterolemic 
(LDL-C 100–190 mg/dL)
Evolocumab Every 2 weeks-12 weeks 70 mg 
105 mg 140 mg
41.0 
43.9 
50.9
[68]
Evolocumab Every 4 weeks-12 weeks 
280 mg 350 mg 420 mg
39 
43.5 
48
Ezetimibe 10 mg/day 14.7
Evolocumab – 
GAUSS
- High cardiovascular risk-intolerant to statins. 
- Taking Statins
Evolocumab Every 4 weeks-12 weeks 
280 mg 350 mg 420 mg
41 
43 
51
[69]
Evolocumab 420 mg+Ezetimibe 10 mg 
Every 4 weeks-12 weeks
63
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without correlations between the risk of dementia and low 
LDL-C.
Regarding alirocumab, cognitive disorders were reported of 
about 0.9% in patients treated vs. 0.7% with placebo. Clinical 
trials of PCSK9i did not show signals of new-onset diabetes, 
though their median follow-up is relatively short [88,89]. Three 
recent mendelian randomizations studies suggested that long- 
term lack of PCSK9 activity (genetically dysfunction) may pre-
dispose an increased risk of type 2 diabetes mellitus [90–92]. A 
recent study in mice showed that even if PCSK9 LOF genetic 
variants are associated with higher plasma glucose levels and 
increased risk of type 2 diabetes, anti-PCSK9 therapies might 
have a limited effect on the incidence of diabetes. It is because 
PCSK9 controls LDLR expression in pancreatic beta-cell, but 
this effect is most probably correlated to locally produced 
PCSK9 [93]; since mAbs target mainly circulating PCSK9, they 
might have a limited impact on beta-cell dysfunction. 
However, in diabetic patients, it would be interesting to eval-
uate how the PCSK9i correlates with the effects of anti-dia-
betic agents [94] on the pancreatic beta cells.
5.3. Cost-effectiveness
According to EAS/ESC guidelines, the treatment algorithm 
for pharmacological LDL-C lowering is utilizing statins as the 
first-line treatment at the highest tolerated dose. However, 
if the goal is not reached, ezetimibe is recommended to 
reach the level of LDL-C < 55 mg/dL [95]. Furthermore, if 
the combination of statin and ezetimibe does not achieve 
the LDL-C goal level, PCSK9i treatment could be initiated in 
primary prevention patients at very high risk, but without 
FH; and in secondary prevention in patients at very high 
risk. The effectiveness of PCSK9i (currently in use alirocumab 
and evolocumab), proved the reduction of LDL-C levels by 
50–60%, with an improvement of cardiovascular outcomes 
and without adverse events [91]. However, due to their high 
costs, the use of PCSK9i is limited only when first-line 
treatment did not obtain the desirable effects. Based on 
estimated costs of PCSK9i, 14,000 USD per person per year 
in the US and 5,000–7,000 USD per person per year in 
Europe, the treatment is not considered to be cost-effective 
for all the patients [96]. The data from FOURIER study 
suggest that the costs should be reduced by 71% to be 
considered cost-effective [97]. Hence, real case data in the 
Italian population showed consumption of lipid-lowering 
agents in 2018 stood at 92.5 defined daily dose (DDD)/ 
1000 inhabitants per day, with an increase of 4.2% respect 
to 2017 and 20% in comparison with 2013. Notably, signifi-
cant increases are observed for ezetimibe alone or in asso-
ciation (+13.2%) and for PCSK9i (+264.8 %). In 2018 statins 
remained in first place in terms of expenditure/capita (7.89 
€/capita), showing a decrease in costs both when they are 
used as monotherapy or in association with other lipid 
modifiers (Tables 3 and 4) [98]. In line with this data, a 
study in the German population showed comparable results 
[99]. In the USA, the cost of PCSK9i needs to be reduced 
from 14.350 USD to 4,536 USD per annum in patients with 
heterozygous FH or atherosclerotic cardiovascular disease 
(ASCVD) to be considered cost-effective [100]. Alternatively, 
in the UK, NICE guidance identifies the LDL-C level at which 
Table 2. Summary of phase III clinical trials with alirocumab or evolocumab. Study design and endpoint as a reduction in LDL-C plasma levels. The total number of 
patients enrolled: 4581.
mAb – Study Name Patients enrolled Treatment LDL reduction (%) Ref.
Evolocumab- 
MENDEL II
Fasting LDL-C 100–190 mg/dL. Evolocumab 140 mg/Ezetimibe 
Every 2 weeks −12 weeks
55–57 more than placebo 
38–40 more than ezetimibe
[62]
Evolocumab 420 mg/Ezetimibe Every 
4 weeks −12 weeks
Evolocumab- 
LAPLACEII
- Subjects not taking a statin LDL-C of at  
least 150 mg/dL  
- Subjects on a non-intensive statin with LDL- 
C ≥ 100 mg/dL 
-Subjects on an intensive statin with LDL-C ≥ 80 mg/ 
dL
Evolocumab 140 mg+ Statin Every 
2 weeks 12 weeks vs. placebo or 
Ezetimibe
66–75 vs. placebo [78]
Evolocumab 420 mg+ Statin 
Every 4 weeks 12 weeks vs. placebo or 
Ezetimibe
63–75 vs. placebo
Evolocumab - 
DESCARTES
- Fasting LDL-C ≥ 75 mg/dL and meeting the following 
LDL-C values on background lipid-lowering therapy: 
- < 100 mg/dL for subjects with CHD or CHD risk 
equivalent 
- < 130 mg/dL for subjects without diagnosed CHD or 
CHD risk equivalent
Evolocumab 420 mg Once a month 
52 weeks
57 ± 2.1 [79]
Evolocumab- 
GAUSS2
- No statin or low dose of Statin with stable 
- History of intolerance to at least 2 Statins 
- Subject not at LDL-C goal
Evolocumab 140 mg Every 2 weeks 
12 weeks vs. placebo or Ezetimibe
53–56 from baseline, 
corresponding to 37–39 vs. 
ezetimibe
[80]
Evolocumab 420 mg Every 4 weeks 
12 weeks vs. placebo or ezetimibe
Evolocumab - 
RUTHERFORD
- Diagnosis of heterozygous familial 
hypercholesterolemia 
- Fasting LDL-C ≥ 100 mg/dL 
- Taking Statin or other lipid-lowering therapies
Evolocumab Every 2 weeks 12 weeks vs. 
placebo
59,2 [81]
Evolocumab Every 4 weeks 12 weeks vs. 
placebo
61,3
Alirocumab- 
ODISSEY- 
ALTERNATIVE
- Primary hypercholesterolemia 
- Statin intolerance
Alirocumab 75 mg Every 2 weeks 
24 weeks
45 ± 2.2 (Alirocumab) vs. 
14.6 ± 2.2 (Ezetimibe) 
Mean difference: 30.4 ± 3.1
[82]
Ezetimibe 10 mg/d 24 weeks
Atorvastatin 20 mg/d 24 weeks
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incremental cost-effectiveness ratio (ICER) could be consid-
ered a cost-effective use of NHS recourses, based on max-
imum acceptable ICER [101].
6. Effects of PCSK9i beyond the LDL
Ever since the discovery of the role of PCSK9 on the 
regulation of the LDLR expression and LDL-C levels, under-
standing its interaction with other lipoproteins is still under 
investigation [2]. High-density lipoprotein (HDL) plays a 
central role in reverse cholesterol transport from peripheral 
tissues to the liver, as a mechanism to relieve cells from 
cholesterol burden. HDL precursors are formed by the liver 
and intestine through the absorption of free cholesterol 
from cell membranes, as APO1 activates cholesterol acyl-
transferase (LCAT) enzyme, which in turn esterifies the free 
cholesterol [102]. Thus, following different metabolic path-
ways, HDL particles interact with the hepatic SR-BI receptors 
resulting in selective uptake of cholesterol or CEPT- 
mediated transfer of cholesterol from HDL to ApoB-contain-
ing lipoproteins. Under normal conditions, the rate of cho-
lesteryl-ester transfer is relative to the rate of HDL and LDL 
catabolism. On the other hand, the degradation of LDLR by 
PCSK9 would increase the acceptor ApoB, enhancing the 
CEPT-mediated transfer of TG and cholesterol esters 
between plasma proteins. Specifically, the role of PCSK9 in 
HDL metabolism is still controversial. Fan et al. demon-
strated how lipoproteins alter the capacity of PCSK9 to 
self-associate forming dimers and trimers, which in turn 
seem to increase the degradation of the LDLR. Based on 
this, in vitro, human and mice HDL significantly inhibited 
PCSK9 self-association as well as in vivo, the incubation of 
PCSK9 with mouse serum demonstrated the association of 
PCSK9 with HDL and LDL, but not with VLDL [103]. 
Moreover, HEK293 cells expressing VLDLR and apoER2 
exposed to PCSK9 showed decreased cellular levels of 
these receptors due to the downregulation of PCSK9, as 
both VLDLR and apoER2 bind to VLDL, it remains unclear 
whether these receptors play a role in human triglyceride 
metabolism [104]. However, more comprehensive studies 
are needed to reveal the potential association of PCSK9 
with different lipoproteins. For instance, it has been shown 
the mechanism by which PCSK9 controls HDL-C levels by 
regulating the ApoE-containing HDL. Based on preclinical 
data that need to be validated in the human condition, in 
PCSK9 KO mice and hLDLR transgenic mice, the concentra-
tions of HDL-C and ApoE-containing HDL are decreased due 
to the overexpression of LDLR. However, apart from the fact 
that LDLR plays an essential role in the PCSK9 regulation of 
HDL-C, it has been shown that PCSK9 mediates the regula-
tion on the presence of ApoE [105]. Following this, the 
reduction of HDL-C concentration and cholesterol efflux by 
PCSK9 inactivation does not have any impact in early ather-
ogenesis. In this context, the absence of ApoE increases by 
2-fold the PCSK9-LDL bound while decreases by 1,5-fold the 
binding with HDL. Further studies will be necessary to 
evaluate the effect of HDL on PCSK9 assembly and the 
mechanism by which it occurs.
From a therapeutic standpoint, the results of clinical 
trials documented that patients treated with alirocumab 
experienced an HDL-C increase of 5–10% [106]. According 
to a real-world study, PCSK9 inhibition treatment 
increased VLDL size significantly and reduced VLDL-asso-
ciated lipoproteins apoE, apoCII, apoCIII; these findings 
reflect the higher clearance of atherogenic VLDL remnants 
by PCSK9i, as a promising approach in lowering cardiovas-
cular risks beyond LDL-C reduction [107]. Besides, the data 
suggest that plasma levels of PCSK9 are predominantly 
related to the IDL fraction in subjects with dysbetalipo-
proteinemia due to apoE2/E2 homozygosity affecting 
plasma triglycerides (TGs) [108]. Another possible target 
is considered to be also the cholesterol ester transferase 
protein (CEPT) inhibitors, which block the exchange of 
cholesteryl esters from HDL to VLDL and LDL. The experi-
mental data on liver tissue of mice fed with high choles-
terol diet showed that CEPT-inhibitors as Anacetrapib 
negatively regulates gene expression of LDLR and PCSK9 
through the inhibition of SREBP2, independently from 
CEPT inhibition [109]. A more comprehensive study 
would include in vivo the effect of CEPT inhibitors on 
LDL-C metabolism through LDLR/PCSK9 pathway. 
Together, yet it is not clear whether these treatments, 
including also the statins therapy, can increase the HDL 
concentration due to the ability to modulate the transfer 
of the cholesterol from HDL to LDL. More research is 
needed to understand the possible role of PCSK9 in the 
HDL- mediated reverse cholesterol transport.
Table 3. Lipid-lowering agents, prescription by therapeutic category in 2018 [98].
Total 
costs
% costs 
of NHS
Cost per 
capita (€)
% 
17– 
18
DDD*/ 
1000 
Ab die
%17- 
18
Hypolipidemic  
agents
870.5 4.0 14.39 −20.1 92.5 4.2
Statins 477.8 2.2 7.90 −25.0 77.4 3.3
Ezetimibe 225.1 1.0 3.72 −26.2 8.1 13.2
Omega 3 112.8 0.5 1.86 0.3 4.3 5.2
PCSK-9 inhibitors 25.0 0.1 0.41 >100 0.1 >100
Fibrates 22.9 0.1 0.38 2.5 2.7 3.0
MTP inhibitors 6.9 0.0 0.11 16.3
Statins and fibrates <0.05 0.0 0.00 −76.0 <0.05 −75.0
*defined daily dose 
Table 4. Analysis of costs of lipid-lowering therapies in Italy 2017 vs. 2018 [98].
Hypolipidemic agents OSMED 2017 OSMED 2018 Difference
Statins € 638.300.000 € 477.800.000 € 160.500.000
Ezetimibe € 305.500.000 € 225.100.000 € 80.400.000
Omega 3 € 112.500.000 € 112.800.000 € 300.000
Fibrates € 22.200.000 € 22.900.000 € 700.000
PCSK9i € 6.600.000 € 25.000.000 € 18.400.000
MTP inhibitors € 5.900.000 € 6.900.000 € 1.000.000
Total € 1.091.000.000 € 870.500.000 € 220.500.000
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7. Non-antibody approaches
An alternative approach to the use of mAbs that blocks the 
PCSK9 function could be targeting the gene expression to 
suppress PCSK9 production. There are several non-antibody 
approaches under translation/development either in the sup-
pression of the function of PCSK9 or inhibiting its gene expres-
sion (Figure 1).
7.1. New drugs currently under clinical evaluation and 
development
7.1.1. Small interfering RNA (inclisiran)
Among new therapies that aim to reduce the circulating 
PCSK9, small interfering RNA (siRNA) has been used to target 
the hepatic production of PCSK9. siRNA are short nucleotide 
RNA molecules that prevent translation by interfering with the 
expression of specific genes with complementary nucleotide 
sequences, thus affecting the degradation of mRNA [110]. 
Based on this approach, inclisiran is a long-acting synthetic 
siRNA, subcutaneously delivered, modified with a combination 
of phosphorothioate, 2ʹ-O- methyl nucleotide and 2ʹ-fluoro 
nucleotides to improve the molecule stability. The siRNA mole-
cule directed against PCSK9 is conjugated with triantennary N- 
acetylgalactosamine carbohydrates, which binds the liver-asia-
loglycoprotein receptors, leading to preferential uptake of 
inclisiran into hepatocytes. According to preclinical data in 
nonhuman primates, a dose of 3 mg/kg resulted in 80% 
reduced in plasma PCSK9 levels and more than 60% LDL-C 
reduction, with the reduction lasting more than 30 days [111].
The phase 1 study tested the side-effect and pharmacody-
namic profile of inclisiran administrated in single and multiple 
doses in healthy volunteers with an average LDL-C level of 
100 mg/dL. Following a single dose of 300 mg, reductions in 
PCSK9 level up to 83.8% and in LDL-C level of up to 59.7% 
were observed, as the administration of inclisiran every 3 or 
6 months provides effective management of hypocholestere-
mia with no adverse effects and no significant changes in the 
QTc interval for heart rate [112]. In a follow-up, Orion-1 was a 
phase 2, double-blind, placebo-controlled, dose-finding study 
in 501 patients with a high risk of CVD with LDL-C levels > 
70 mg/dL in the presence of atherosclerotic history or LDL- 
C > 100 mg/dL in the absence of risk of ASCVD history. The 
studies report on day 180 a significant reduction of LDL-C up 
to 50 mg/dL level that was obtained with two doses of 300 mg 
inclisiran at 48% of patients [113]. The ORION-7 study evalu-
ated the effect of inclisiran on pharmacokinetics (PK) and 
pharmacodynamics (PD) in individuals with different degrees 
of renal impairment. According to data, individuals with renal 
impairment have greater exposure to plasma but without 
influence on the PD response [114]. Phase III clinical trials, 
ORION-10 and ORION-11, enrolled 1561 and 1617 patients 
with atherosclerotic cardiovascular disease or with equivalent 
risk who had LDL-C level elevated despite receiving statin 
therapy. A regimen of inclisiran injections on day 1, day 90 
and every six months reduced levels of LDL-C by 49.2% to 
52.2% compared to placebo as the level was decreased mostly 
in all patients receiving Inclisiran [115]. However, the total 
number of any potential benefits on cardiovascular outcomes 
was too small to conclude, a question that will be tested in 
ongoing cardiovascular trials. Following this, Orion-8 is a 
phase III extension of Orion-5,-9,-10,-11 measuring the effect 
of long term of Inclisiran in subjects in high cardiovascular risk 
and elevated LDL-C. Results from ORION-11 demonstrated that 
the rate of the adverse events was similar between placebo 
and treated arm as well as the cardiovascular endpoint such as 
cardiac death, cardiac arrest, MI and stroke occurred in 7,8% of 
patients treated with Inclisiran, while it was 10.3% for the 
placebo group. To further establish the safety, tolerability 
and efficacy, ORION-4, a phase III double-blinded, will be con-
ducted in 150 sites across the UK and USA to assess the effects 
of 300 mg SC at day Inclisiran on MACE among the subjects 
with ASCVD [116].
In summary, a siRNA therapeutic agent targeting PCSK9 
represents a promising way in the management of hypercho-
lesterolemia with significant reductions of circulating levels of 
both PCSK9 and LDL-C without adverse events in patients with 
renal impairment and diabetes.
7.1.2. Antisense oligos
A 14-mer oligonucleotide with locked nucleic acid (LNA) 
modifications can act as an antisense inhibitor complemen-
tary to PCSK9, decreasing intra and extracellular protein 
levels. The oligonucleotide contains β-D-oxy-LNA and 
eight deoxynucleotides with modified internucleotide to 
increase binding affinity and resistance. The preclinical 
data on mice and nonhuman primates have shown no 
rate-limiting toxicity on kidney and liver function without 
nephropathy signs. In human clinical trials, the starting 
dose in the randomized, double-blind, placebo-controlled 
study was 0.5 mg/Kg administered to healthy with slightly 
increased LDL-C levels. The primary endpoints resulted in 
decreased levels of plasma PCSK9 and LDL-C and ApoB. 
However, the highest dose of 5 mg/Kg reduced PCSK9 
concentrations up to 50%, and 25% of LDL-C compared 
to baseline but with transient renal tubular toxicity [117]. 
In the future, a better understanding of the molecular 
mechanism of SPC5001 is required to minimize the off- 
target gene toxicity.
7.2. Approaches under development
Apart from the mentioned approaches, several different 
ways are undergoing to develop a new way to block 
PCSK9 [118]. Small-molecule inhibitors have been devel-
oped as a promising therapy to disrupt the interaction of 
the PCSK9 and LDLR or blocking the gene expression of 
PCSK9, with the advantage of oral administration and 
lower production costs than mAbs. A new cholesteryl 
ester transfer protein (CETP) inhibitor, K-312, reduces 
the PCSK9 expression and LDL-C level via a mechanism 
independent of CETP inhibition. Based on experimental 
data, in vivo, K-312 administered to rabbits after two 
weeks led to a 63% reduction of PCSK9’s transcript 
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levels in the liver and increased the high-density lipo-
proteins- cholesterol levels [119]. Another molecule 
PF846 has been proposed to block PCSK9 by interfering 
with the elongation phase of translation. The ribosome 
profiling showed that PF846 is a highly selective inhibi-
tor of PCSK9 translation with no sign of toxicity in vivo 
[23]; however, the product was discontinued. Other 
known small molecules can reduce the PCSK9 synthesis 
or its function. Among them, only O-304 (an activator of 
5′ adenosine monophosphate-activated protein kinases 
(AMPK) developed by Betagenon) is in clinical trials for 
type 2 diabetes treatment; however, it can reduce the 
PCSK9 level significantly as well [120].
Annexin A2, an extracellular endogenous antagonist, binds 
to the C-terminal domain of PCSK9, inhibiting the degradation 
of LDLR. Thus, the adenoviral overexpression of AnxA2 in the 
liver results in an increase of LDLR levels. Meanwhile, an 
increase of 2-fold in circulating PCSK9 levels was observed in 
AnxA2 knockout mice [121]. Further studies at the level of 
clinical trials are necessary to identify the physiological role 
of Annexin A2.
CRISPR/Cas9 is a gene-editing tool that consists of a single 
guide RNA (gRNA) and Cas9 endonuclease as DNA-mediated 
cleavage generates a double-strand break that triggers DNA 
repair machinery [122]. The PCSK9 gene-editing technique 
has shown to disrupt the PCSK9 gene in mice liver, reducing 
the cholesterol level by 35–40% in knockout mice compared 
with wild-type mice [123]. Another recent work on a huma-
nized mouse model expressing hPCSK9 specifically at liver 
showed the efficacy and feasibility of Cas9 guided gene 
editing of liver-specific PCSK9 [124]. Currently, due to being 
relatively straightforward from the experimental point of 
view, several preclinical activities are ongoing on the differ-
ent animal models, such as nonhuman primates. However, 
the severe limitation here is the presence of many off-target 
mutations with a higher frequency rather than the intended 
mutation; thus, the designed sgRNA needs to be highly 
specific for long-term term benefit and safety in human 
subjects.
For long-term PCSK9 inhibition, the peptide-based 
vaccination stimulates the immune system to generate 
high-affinity antibodies as well as to block the ability of 
PCSK9 to bind to LDLR. AT04A, a peptide-based anti- 
PCSK9 vaccine, mimics human mature PCSK9 protein, 
conjugated to a carrier protein that provides T-helper 
cell epitopes. The LDL-C and total cholesterol levels 
were reduced up to 30–50% in anti-PCSK9 immunized 
mice as the atherosclerotic plaques were down by 64% 
in the affected blood vessels [24]. However, the active 
immunization might cause cell-mediated cytotoxicity 
with non-specific cell destruction.
8. Concluding remarks and future perspectives
Anti-PCSK9 mAbs therapy has become one of the pillars in the 
control of dyslipidemias, specifically hypercholesterolemia. In 
this review, we have summarized the current state of under-
standing regarding the PCSK9 molecular mechanisms of 
action and the clinical use of the inhibition of this protein to 
manage the patients with high levels of apo B containing 
lipoproteins. Several new approaches to reduce PCSK9 activ-
ity/plasma levels are under development, and some will be 
shortly available for clinical use (such as inclisiran); some 
others are at the early stages of development or not biologi-
cals. The related clinical studies have indicated that reducing 
PCSK9 is per se safe, off-target effects of the drug, however, 
need to be carefully studied.
9. Expert opinion
The use of biologicals in the therapy of hypercholesterolemia 
is a relatively recent addition to the medical armamentarium. 
However, even in the short term of availability of biologicals, 
they have profoundly contributed to our understanding about 
the role of LDL lowering at both the experimental and clinical 
levels. As of today, we have definitely been able to prove that 
the benefit of LDL-C lowering is independent of the approach 
that is being used but only proportional to LDL (Apo B) 
reduction. Further, deficient levels of LDL-C induced by ther-
apy are safe and do not trigger specific adverse effects. 
Ultimately, we have been able to target specific pathways by 
different approaches (monoclonals vs. siRNAs) with the possi-
bility of addressing whether tissue-specific reductions of 
PCSK9 have different effects as compared with general inhibi-
tion of PCSK9 in circulation. Targeting RNA is a challenging 
approach, although, for this, we do need long term safety data 
as the intracellular levels of PCSK9 are also likely to be 
reduced. Whether this effect has consequences on the hepa-
tocyte needs further studies; to date, no specific adverse 
events have been reported. Finally, the link between insulin 
secretion and local PCSK9 production remains to be addressed 
to reconcile the genetic data with the data from the clinical 
trials.
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